October 2018
From the Editor-In-Chief: Getting to The Prestige in Cancer Care
October 19th 2018“Every great magic trick consists of three parts or acts. The first part is called ‘The Pledge.’ The magician shows you something ordinary. ...The second act is called ‘The Turn.’ The magician takes the ordinary something and makes it do something extraordinary. Now you’re looking for the secret, but you won’t find it, because of course you’re not really looking...Every magic trick has a third act, the hardest part, the part we call ‘The Prestige.’” — Christopher Priest, The Prestige
The Nobel Prize: Checkpoint Inhibitors
October 18th 2018Nobel Prize winner James Allison, PhD, pioneering T-cell researcher, said the award represents the triumph of science and shows the value of research, even if it does not immediately lead to a scientific or commercial success.
Medical Marijuana in Cancer Treatment: No Standards of Care, and So Far, No Coverage
October 16th 2018Over the past decade, both recreational and medical marijuana use in the United States has grown tremendously. However, disputes surrounding the legal and ethical implications, safe administration, dispensing, health consequences, and therapeutic indications– albeit based on very limited clinical data– related to its usage abound.
Survey of NCI-Designated Cancer Centers Finds Most Are Out-of-Network on Exchanges
October 15th 2018The National Comprehensive Cancer Network (NCCN) in collaboration with Avalere Health present survey results examining the experiences National Cancer Institute (NCI)-designated cancer centers have had with the marketplaces, the implications for patients' access to cancer care, and proposed policy solutions.
